

## **Appili Therapeutics**

**Symbol:** TSX: APLI | OTCQX: APLIF

**Market Cap:** 9M

**Sector:** Biotech

**Purpose:** Raise Awareness / Open Market Buying

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring a Phase 3 clinical trial evaluating oral antiviral Avigan®/REEQONUSTM (favipiravir) for the worldwide treatment of COVID-19. The Company's broader portfolio includes a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two antibiotic programs.

### **Investor Bullet Points:**

- **ID Portfolio Company** built to identify and advance promising infectious disease (ID) programs, with a skilled leadership team in advancing programs with upside potential.
- **Diversified Pipeline** of 5 programs with multiple near-term milestones. Including a Late-Stage asset - Phase 3 COVID antiviral program with data readout in Q3 2021. Priority Review Vouchers associated with 3 of the programs.
- **Business Development;** Active in-licensing / partnering to expand clinical programs and accelerate commercialization.

### **Armand Balboni, CEO**

Armand Balboni's career includes medical research and drug development experience in civilian, academic, and military organizations, most recently as a partner at Bloom Burton & Co. where he was the firm's senior advisor for regulatory and medical affairs. As an active-duty military officer, Dr. Balboni served as a staff officer at the U.S. Army Research Institute of Infectious Diseases (USAMRIID). He completed a military staff fellowship at the U.S. Food and Drug Administration and went on to serve as the deputy director of clinical and regulatory affairs for the U.S. Army. Armand completed his doctoral work in the MD/PhD program at the Icahn School of Medicine at Mount Sinai and earned his law degree at Brooklyn Law School.